Core Viewpoint - The brain-computer interface (BCI) sector is experiencing significant growth driven by favorable policies, technological advancements, and increased investment interest, as evidenced by the recent surge in stock prices of related companies in both Hong Kong and A-share markets [2][6][7]. Policy Developments - The National Medical Products Administration has included implantable brain-computer interface medical devices in the "Priority Approval List for High-end Medical Devices (2025 Edition)" [2]. - A joint initiative by seven ministries, including the Ministry of Industry and Information Technology, has set phased goals for the BCI industry by 2027 and 2030 [3]. - The "14th Five-Year Plan" emphasizes the BCI sector as a key area for fostering new economic growth [4]. - The National Healthcare Security Administration has introduced new pricing guidelines for invasive BCI procedures, facilitating reimbursement pathways [4]. Technological Advancements - Recent breakthroughs in BCI technology include the first domestically developed fully implanted, wireless BCI product by Brain Tiger Technology, which successfully completed its first clinical trial [5]. - The National Medical Products Administration has approved the world's first invasive BCI product for treating addiction-related mental disorders [5]. - Ongoing clinical trials and collaborations among research institutions and medical units are yielding significant progress in the field [5]. Market Insights - The BCI industry is entering a rapid commercialization phase, supported by policy backing, technological breakthroughs, and increased capital influx [5][6]. - The market for BCI is projected to be a nearly $10 billion opportunity globally, with domestic companies making strides in flexible electrodes and real-time Chinese language decoding [7]. - Investment interest in the BCI sector is rising, particularly in rehabilitation applications and non-invasive BCI technologies, as companies strategically position themselves for future growth [6][7].

心玮医疗-B(06609)发布公告，于2025年12月29日斥资299.15万港元回购5.61万股。 ...

Group 1 - The company, Heartway Medical-B (06609.HK), announced a share buyback plan on December 29, 2025, involving an expenditure of HKD 2.99 million to repurchase 56,000 shares [1] - The buyback price per share is set between HKD 52.5 and HKD 53.75 [1]

Core Viewpoint - Heartway Medical-B (06609) announced a share buyback plan, intending to repurchase 56,100 shares for a total cost of HKD 2.9915 million by December 29, 2025 [1] Group 1 - The company plans to spend HKD 2.9915 million on the buyback [1] - The total number of shares to be repurchased is 56,100 [1] - The buyback is scheduled to be completed by December 29, 2025 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 上海心瑋醫療科技股份有限公司 (於中華人民共和國註冊成立的有限責任公司) 呈交日期： 2025年12月29日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 H | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 06609 | 說明 H股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | 事件 | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 ...

Core Viewpoint - The stock of Xinwei Medical-B (6609.HK) surged over 12%, reaching a peak of 54.05 HKD, driven by positive market sentiment regarding brain-computer interface (BCI) technology and its commercial potential in a nearly 10 billion USD market [1]. Industry Summary - The brain-computer interface sector is at a critical stage characterized by increased policy support, rapid technological advancements, and accelerated commercialization [1]. - The market for BCI technology is projected to be a nearly 10 billion USD blue ocean market, indicating significant growth opportunities [1]. Company Summary - Xinwei Medical is highlighted as a key player in the BCI space, benefiting from advancements in invasive, semi-invasive, and interventional technologies that offer unmatched advantages in signal quality and control precision [1]. - Domestic companies, including Xinwei Medical, have made technological breakthroughs in flexible electrodes and real-time Chinese language decoding, contributing to the acceleration of domestic substitution and showcasing significant long-term growth potential [1].

心玮医疗-B(6609.HK)大涨超12%，最高触及54.05港元。 本文源自：金融界AI电报 ...

Group 1 - The Hong Kong stock market's brain-computer interface sector experienced a collective surge, with notable increases in various companies' stock prices [1] - Xinwei Medical-B saw a rise of over 12%, while Brain Dynamics and Nanjing Panda Electronics both increased by over 7% [1] - Brainhole Technology rose by over 5%, and Micron Brain Science experienced an increase of over 3% [1]

Core Viewpoint - The brain-machine interface sector is experiencing a surge in stock prices following the release of a new regulatory framework by the National Medical Products Administration (NMPA) in China, which includes a list of prioritized high-end medical devices for approval [1] Group 1: Stock Performance - Heartway Medical-B (06609) saw a price increase of 12.22%, reaching 54 HKD [1] - Brain Dynamics-B (06681) rose by 7.78%, trading at 6.79 HKD [1] - Nanjing Panda Electronics (00553) increased by 7.14%, with a price of 4.65 HKD [1] Group 2: Regulatory Developments - On December 26, the NMPA published the "Priority Approval List for High-End Medical Devices (2025 Edition)," which includes eight products, such as implantable brain-machine interface devices [1] - The list outlines the technical parameters and expected uses of the products [1] - The NMPA is actively promoting faster and better market entry for brain-machine interface devices through a dedicated working meeting [1] Group 3: Market Outlook - Guotai Junan Securities notes that recent policies have shown strong support for innovation in medical devices [1] - The brain-machine interface sector has diverse application scenarios and rich product and research pathways, indicating significant future potential [1] - With the support of product registration and medical insurance policy initiatives, commercialization is expected to accelerate [1]

Group 1 - The Hong Kong stock market's brain-computer interface sector experienced a collective surge, with notable increases in stock prices for several companies [1] - Heartway Medical-B saw a rise of over 12%, while Brain Dynamics-B and Nanjing Panda Electronics both increased by over 7% [1] - The Fifth Frontier Brain Science and Industry Conference and the 2025 Shenzhen Brain-Computer Interface Expo commenced on December 28, marking the official launch of the "Guangdong-Hong Kong-Macau Greater Bay Area Brain Science and Central Nervous System Disease AI Innovation Alliance" [1] Group 2 - Heartway Medical-B's latest price is 54.000, with a total market capitalization of 2.069 billion and a year-to-date increase of 146.01% [2] - Brain Dynamics-B's latest price is 6.790, with a total market capitalization of 8.598 billion and a year-to-date increase of 110.87% [2] - Nanjing Panda Electronics' latest price is 4.650, with a total market capitalization of 4.249 billion and a year-to-date increase of 35.57% [2] - Brainhole Technology's latest price is 0.230, with a total market capitalization of 0.0184 billion and a year-to-date increase of 1.77% [2] - Microneuroscience's latest price is 11.000, with a total market capitalization of 6.336 billion and a year-to-date increase of 30.18% [2]